Skip to content

Rice Bran-based Supplemental Foods for the Treatment of Childhood Malnutrition

Rice Bran in Ready-to-use Therapeutic Foods for Microbiota-targeted Treatment of Childhood Malnutrition

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05319717
Enrollment
200
Registered
2022-04-08
Start date
2022-12-01
Completion date
2023-08-31
Last updated
2024-06-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe Acute Malnutrition

Brief summary

The purpose of this study is to assess the efficacy of treating children with severe acute malnutrition (SAM) with a locally produced ready-to-use therapeutic food (RUTF) with or without rice bran.

Detailed description

Rice bran is a nutrient dense food ingredient with prebiotics and phytochemicals, as well as vitamins, fatty acids, and amino acids. The investigators will determine if the inclusion of rice bran to locally produced RUTFs will improve SAM treatment for children in Indonesia. This will be assessed by standard anthropometric measures and determining the modulation of the malnourished child's gut microbiome and metabolome. The study will also assess rates of relapse in the entire cohort. This study will yield new information of direct importance and impact to public health nutrition and advance our knowledge and treatment of SAM in Indonesia. Investigation of the gut-microbiota metabolism following consumption of rice bran provided in RUTFs compared to RUTF without rice bran included will provide key mechanistic insights for repairing nutrient absorptive functions in the gut, sustaining gut health in treated children and inform long-term treatment solutions for SAM.

Interventions

DIETARY_SUPPLEMENTReady-to-use therapeutic food with heat stabilized rice bran

Children assigned to the experimental group will be treated for severe acute malnutrition with a novel ready-to-use therapeutic food that contains 5% heat stabilized rice bran.

DIETARY_SUPPLEMENTReady-to-use therapeutic food (no rice bran)

Children assigned to the active comparator group will be treated for severe acute malnutrition with a novel ready-to-use therapeutic food (no rice bran).

Sponsors

Thrasher Research Fund
CollaboratorOTHER
Savica, Indonesia
CollaboratorUNKNOWN
Institute of Research for Development, France
CollaboratorOTHER_GOV
Colorado State University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Intervention model description

Control study arm: Locally produced Ready to use therapeutic food (RUTF) Intervention study arm: Locally produced Ready to use therapeutic food plus rice bran (RUTF+RB)

Eligibility

Sex/Gender
ALL
Age
6 Months to 59 Months
Healthy volunteers
No

Inclusion criteria

* Willing to participate in the study, with parent(s) signing the informed consent. If the caretaker denies the participation of the child, the child will be enrolled for treatment through the health system, but the information will be not considered for the purpose of the trial. * Child identified with a weight-for-height z-score WHZ of \< -2.5 (SAM children and children with advanced moderate acute malnutrition) and/or mid-upper arm circumference (MUAC) \<115 mm) or a child with mild to moderate nutritional edema (regardless of anthropometry). * Being qualified for outpatient treatment. * Aged 6-59 months old upon enrolment * Pass appetite test (taste test) (as stipulated by WHO guidelines on the treatment of SAM). See appetite test document attached. * Not having consumed RUTF in the last two months

Exclusion criteria

* Children detected with severe acute malnutrition younger than 6 months of age will be excluded from the project, as well as any child with a body weight \<4.0 kg. * Children 6-59 months old who, when diagnosed with SAM, have been detected with medical complications, with TB, HIV positive status, one or more signs from the Integrated Management of Childhood Illness (IMCI) guidelines, severe oedema (+++) or who have failed the appetite test (see appetite test document attached). * Medical complications include: Cough/difficulty in breathing; Diarrhea; Fever; Ear Problems. IMCI signs will be identified according to WHO definition and include not able to drink or breastfeed; vomiting; convulsions; lethargy. * Participating in another clinical trial * Any congenital disorder that interferes with normal nutrient intake; chronic conditions including but not exclusively disorders of heart, kidney or liver (children to be screened by a physician). * SAM with complications requiring hospital treatment. (Upon discharge from hospital, the child will be re-evaluated for inclusion in the study). * Siblings will not be allowed to participate in the trial Withdrawal criteria: * Not consuming the RUTF supplementation at all in \>4 days a week in 2 consecutive weeks. * Not providing samples or completing forms/questionnaires at study visits * Developing medical complications requiring hospitalization * Not gaining weight after 1 month of treatment * Major reactions to intervention

Design outcomes

Primary

MeasureTime frameDescription
Efficacy of the locally produced ready-to-use therapeutic food + heat stabilized rice bran as compared to locally produced ready-to-use therapeutic food alone in the treatment of severe acute malnutrition as determined by child weight.Baseline, week 4, week 8, and week 16This will be assessed by measures of: \- Weight
Efficacy of the locally produced ready-to-use therapeutic food + heat stabilized rice bran as compared to locally produced ready-to-use therapeutic food alone in the treatment of severe acute malnutrition as determined by mid-upper arm circumference.Changes between baseline, week 4, week 8, and week 16This will be assessed by measures of: -Mid-upper arm circumference
Efficacy of the locally produced ready-to-use therapeutic food + heat stabilized rice bran as compared to locally produced ready-to-use therapeutic food alone in the treatment of severe acute malnutrition as determined by morbidity.Changes between baseline, week 4, week 8, and week 16This will be assessed by measures of: \- Morbidity (diarrhea, fever, vomiting, upper or lower respiratory infection)

Secondary

MeasureTime frameDescription
Stool microbiota compositionChanges between baseline, week 4, week 8, and week 16Determine stool microbiota composition of infants in both arms over time using 16S rRNA sequencing and shotgun metagenomic sequencing.
Percent of children recoveredBaseline, week 4, week 8, and week 16The number of children recovered in the 4 week treatment period will be determined as well as the time to recovery (days).
Dried blood spot metabolite profileChanges between baseline, week 4, week 8, and week 16Dried blood spots will be analyzed for metabolites.
RelapseWeek 16 (end of study)Determine the number of participants that experience severe acute malnutrition relapse 4 weeks after the treatment/intervention has ended.

Countries

Indonesia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 8, 2026